Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 209

1.

Technical Note: Retrospective Reduction of Systematic Differences Across Scanner Changes by Accounting for Noise Floor Effects in Diffusion Tensor Imaging.

Sakaie K, Zhou X, Lin J, Debbins J, Lowe M, Fox RJ.

Med Phys. 2018 Jul 11. doi: 10.1002/mp.13088. [Epub ahead of print]

PMID:
29998491
2.

Patient-Reported Disease-Modifying Therapy Adherence in the Clinic: A Reliable Metric?

Conway DS, Cecilia Vieira M, Thompson NR, Parker KN, Meng X, Fox RJ.

Mult Scler J Exp Transl Clin. 2018 May 23;4(2):2055217318777894. doi: 10.1177/2055217318777894. eCollection 2018 Apr-Jun.

3.

Temperature influences habitat preference of coral reef fishes: Will generalists become more specialised in a warming ocean?

Matis PA, Donelson JM, Bush S, Fox RJ, Booth DJ.

Glob Chang Biol. 2018 Jul;24(7):3158-3169. doi: 10.1111/gcb.14166. Epub 2018 May 20.

PMID:
29658157
4.

Rare side effects of alemtuzumab remind us of the need for postmarketing surveillance.

Muraro PA, Scolding NJ, Fox RJ.

Neurology. 2018 May 1;90(18):819-820. doi: 10.1212/WNL.0000000000005409. Epub 2018 Mar 30. No abstract available.

PMID:
29602911
5.

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.

Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S, Scherz T, Wolf C, Wallström E, Dahlke F; EXPAND Clinical Investigators.

Lancet. 2018 Mar 31;391(10127):1263-1273. doi: 10.1016/S0140-6736(18)30475-6. Epub 2018 Mar 23.

PMID:
29576505
6.

Corrigendum to 'Effects of Delayed-release Dimethyl Fumarate (DMF) on Health-related Quality of Life in Patients With Relapsing-remitting Multiple Sclerosis: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies: [Clinical Therapeutics 36 (2014) 1958-1971].

Kita M, Fox RJ, Gold R, Giovannoni G, Phillips JT, Sarda SP, Kong J, Viglietta V, Sheikh SI, Okwuokenye M, Kappos L.

Clin Ther. 2018 May;40(5):812. doi: 10.1016/j.clinthera.2018.02.005. Epub 2018 Mar 7. No abstract available.

PMID:
29523369
7.

A survey of dietary characteristics in a large population of people with multiple sclerosis.

Fitzgerald KC, Tyry T, Salter A, Cofield SS, Cutter G, Fox RJ, Marrie RA.

Mult Scler Relat Disord. 2018 May;22:12-18. doi: 10.1016/j.msard.2018.02.019. Epub 2018 Feb 27.

PMID:
29510324
8.

Strategy To Prepare 3-Bromo- and 3-Chloropyrazoles.

Fox RJ, Schmidt MA, Eastgate MD.

J Org Chem. 2018 Mar 2;83(5):2830-2839. doi: 10.1021/acs.joc.7b03282. Epub 2018 Feb 19.

PMID:
29429343
9.

Tissue Markers for Acute Multiple Sclerosis Treatment Response-A Step Toward Personalized Medicine.

Fox RJ.

JAMA Neurol. 2018 Apr 1;75(4):406-407. doi: 10.1001/jamaneurol.2017.4850. No abstract available.

PMID:
29404560
10.

'Stick with your own kind, or hang with the locals?' Implications of shoaling strategy for tropical reef fish on a range-expansion frontline.

Smith SM, Fox RJ, Booth DJ, Donelson JM.

Glob Chang Biol. 2018 Apr;24(4):1663-1672. doi: 10.1111/gcb.14016. Epub 2018 Jan 15.

PMID:
29334689
11.

Treatment satisfaction and bothersome bladder, bowel, sexual symptoms in multiple sclerosis.

Wang G, Marrie RA, Fox RJ, Tyry T, Cofield SS, Cutter GR, Salter A.

Mult Scler Relat Disord. 2018 Feb;20:16-21. doi: 10.1016/j.msard.2017.12.006. Epub 2017 Dec 14.

PMID:
29275057
12.

Shared Decision Making and Autonomy Among US Participants with Multiple Sclerosis in the NARCOMS Registry.

Cofield SS, Thomas N, Tyry T, Fox RJ, Salter A.

Int J MS Care. 2017 Nov-Dec;19(6):303-312. doi: 10.7224/1537-2073.2016-091.

13.

Perspectives on marijuana use and effectiveness: A survey of NARCOMS participants.

Cofield SS, Salter A, Tyry T, Crowe C, Cutter GR, Fox RJ, Marrie RA.

Neurol Clin Pract. 2017 Aug;7(4):333-343. doi: 10.1212/CPJ.0000000000000383.

PMID:
29185555
14.

Advancing trial design in progressive multiple sclerosis.

Fox RJ, Chataway J.

Mult Scler. 2017 Oct;23(12):1573-1578. doi: 10.1177/1352458517729768.

PMID:
29041871
15.

Author response: High hypothetical interest in physician-assisted death in multiple sclerosis.

Marrie RA, Salter A, Tyry T, Cutter GR, Fox RJ.

Neurology. 2017 Sep 26;89(13):1429-1430. doi: 10.1212/WNL.0000000000004437. No abstract available.

PMID:
28947584
16.

Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up.

Hersh CM, Love TE, Bandyopadhyay A, Cohn S, Hara-Cleaver C, Bermel RA, Fox RJ, Cohen JA, Ontaneda D.

Mult Scler J Exp Transl Clin. 2017 Aug 24;3(3):2055217317715485. doi: 10.1177/2055217317715485. eCollection 2017 Jul-Sep.

17.

T1-/T2-weighted ratio differs in demyelinated cortex in multiple sclerosis.

Nakamura K, Chen JT, Ontaneda D, Fox RJ, Trapp BD.

Ann Neurol. 2017 Oct;82(4):635-639. doi: 10.1002/ana.25019. Epub 2017 Sep 21.

PMID:
28833377
18.

DNA methylation in demyelinated multiple sclerosis hippocampus.

Chomyk AM, Volsko C, Tripathi A, Deckard SA, Trapp BD, Fox RJ, Dutta R.

Sci Rep. 2017 Aug 18;7(1):8696. doi: 10.1038/s41598-017-08623-5.

19.

Efficacy and Tolerability of Delayed-release Dimethyl Fumarate in Black, Hispanic, and Asian Patients with Relapsing-Remitting Multiple Sclerosis: Post Hoc Integrated Analysis of DEFINE and CONFIRM.

Fox RJ, Gold R, Phillips JT, Okwuokenye M, Zhang A, Marantz JL.

Neurol Ther. 2017 Dec;6(2):175-187. doi: 10.1007/s40120-017-0077-5. Epub 2017 Aug 2.

20.

Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM.

Fernández Ó, Giovannoni G, Fox RJ, Gold R, Phillips JT, Potts J, Okwuokenye M, Marantz JL.

Clin Ther. 2017 Aug;39(8):1671-1679. doi: 10.1016/j.clinthera.2017.06.012. Epub 2017 Jul 25.

21.

Autologous hematopoietic stem cell transplantation for MS: Safer than previously thought.

Burman J, Fox RJ.

Neurology. 2017 May 30;88(22):2072-2073. doi: 10.1212/WNL.0000000000003995. Epub 2017 Apr 28. No abstract available.

PMID:
28455384
22.

Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis.

Cohen JA, Imrey PB, Planchon SM, Bermel RA, Fisher E, Fox RJ, Bar-Or A, Sharp SL, Skaramagas TT, Jagodnik P, Karafa M, Morrison S, Reese Koc J, Gerson SL, Lazarus HM.

Mult Scler. 2018 Apr;24(4):501-511. doi: 10.1177/1352458517703802. Epub 2017 Apr 6.

PMID:
28381130
23.

Comparative effectiveness of delayed-release dimethyl fumarate versus glatiramer acetate in multiple sclerosis patients: results of a matching-adjusted indirect comparison.

Chan A, Cutter G, Fox RJ, Xiao J, Lewin JB, Edwards MR.

J Comp Eff Res. 2017 Jun;6(4):313-323. doi: 10.2217/cer-2016-0085. Epub 2017 Mar 28.

24.

Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies.

Havrdova E, Giovannoni G, Gold R, Fox RJ, Kappos L, Phillips JT, Okwuokenye M, Marantz JL.

Eur J Neurol. 2017 May;24(5):726-733. doi: 10.1111/ene.13272. Epub 2017 Mar 22.

25.

High hypothetical interest in physician-assisted death in multiple sclerosis.

Marrie RA, Salter A, Tyry T, Cutter GR, Cofield S, Fox RJ.

Neurology. 2017 Apr 18;88(16):1528-1534. doi: 10.1212/WNL.0000000000003831. Epub 2017 Mar 15.

PMID:
28298551
26.

Landscape of MS patient cohorts and registries: Recommendations for maximizing impact.

Bebo BF Jr, Fox RJ, Lee K, Utz U, Thompson AJ.

Mult Scler. 2018 Apr;24(5):579-586. doi: 10.1177/1352458517698250. Epub 2017 Mar 1.

27.

Evidence of activation of the Nrf2 pathway in multiple sclerosis patients treated with delayed-release dimethyl fumarate in the Phase 3 DEFINE and CONFIRM studies.

Gopal S, Mikulskis A, Gold R, Fox RJ, Dawson KT, Amaravadi L.

Mult Scler. 2017 Dec;23(14):1875-1883. doi: 10.1177/1352458517690617. Epub 2017 Feb 3.

PMID:
28156185
28.

Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up.

Hersh CM, Love TE, Cohn S, Hara-Cleaver C, Bermel RA, Fox RJ, Cohen JA, Ontaneda D.

Mult Scler Relat Disord. 2016 Nov;10:44-52. doi: 10.1016/j.msard.2016.08.002. Epub 2016 Aug 8.

PMID:
27919497
29.

Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function.

Ontaneda D, Thompson AJ, Fox RJ, Cohen JA.

Lancet. 2017 Apr 1;389(10076):1357-1366. doi: 10.1016/S0140-6736(16)31320-4. Epub 2016 Nov 24. Review.

PMID:
27889191
30.

Examining the joint effect of disability, health behaviors, and comorbidity on mortality in MS.

Salter A, Tyry T, Wang G, Fox RJ, Cutter G, Marrie RA.

Neurol Clin Pract. 2016 Oct;6(5):397-408.

31.
32.

Quantitative quality assurance in a multicenter HARDI clinical trial at 3T.

Zhou X, Sakaie KE, Debbins JP, Kirsch JE, Tatsuoka C, Fox RJ, Lowe MJ.

Magn Reson Imaging. 2017 Jan;35:81-90. doi: 10.1016/j.mri.2016.08.022. Epub 2016 Aug 30.

33.

Environmental change mediates mate choice for an extended phenotype, but not for mate quality.

Head ML, Fox RJ, Barber I.

Evolution. 2017 Jan;71(1):135-144. doi: 10.1111/evo.13091. Epub 2016 Nov 2.

34.

Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis.

Fox RJ, Chan A, Zhang A, Xiao J, Levison D, Lewin JB, Edwards MR, Marantz JL.

Curr Med Res Opin. 2017 Feb;33(2):175-183. doi: 10.1080/03007995.2016.1248380. Epub 2016 Nov 10.

PMID:
27733070
35.

Inadequate outcome measures are the biggest impediment to successful clinical trials in progressive MS - NO.

Fox RJ.

Mult Scler. 2017 Apr;23(4):506-508. doi: 10.1177/1352458516671205. Epub 2016 Oct 11. No abstract available.

PMID:
27729555
36.

Imaging as an Outcome Measure in Multiple Sclerosis.

Ontaneda D, Fox RJ.

Neurotherapeutics. 2017 Jan;14(1):24-34. doi: 10.1007/s13311-016-0479-6. Review.

37.

Predicting range-shift success potential for tropical marine fishes using external morphology.

Smith SM, Fox RJ, Donelson JM, Head ML, Booth DJ.

Biol Lett. 2016 Sep;12(9). pii: 20160505.

38.

Measuring Brain Tissue Integrity during 4 Years Using Diffusion Tensor Imaging.

Ontaneda D, Sakaie K, Lin J, Wang XF, Lowe MJ, Phillips MD, Fox RJ.

AJNR Am J Neuroradiol. 2017 Jan;38(1):31-38. doi: 10.3174/ajnr.A4946. Epub 2016 Sep 22.

39.

Natalizumab-related PML 2 weeks after negative anti-JCV antibody assay.

Ontaneda D, Fox RJ, Gagne Brosseau MS, Stobbe G, Wundes A.

Neurology. 2016 Aug 30;87(9):957-8. doi: 10.1212/WNL.0000000000003081. No abstract available.

PMID:
27572430
40.

Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis.

Fox RJ, Coffey CS, Cudkowicz ME, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Conwit R, Naismith R, Ashokkumar A, Bermel R, Ecklund D, Koepp M, Long J, Natarajan S, Ramachandran S, Skaramagas T, Thornell B, Yankey J, Agius M, Bashir K, Cohen B, Coyle P, Delgado S, Dewitt D, Flores A, Giesser B, Goldman M, Jubelt B, Lava N, Lynch S, Miravalle A, Moses H, Ontaneda D, Perumal J, Racke M, Repovic P, Riley C, Severson C, Shinnar S, Suski V, Weinstock-Gutman B, Yadav V, Zabeti A.

Contemp Clin Trials. 2016 Sep;50:166-77. doi: 10.1016/j.cct.2016.08.009. Epub 2016 Aug 10.

41.

Characterizing absolute lymphocyte count profiles in dimethyl fumarate-treated patients with MS: Patient management considerations.

Fox RJ, Chan A, Gold R, Phillips JT, Selmaj K, Chang I, Novas M, Rana J, Marantz JL.

Neurol Clin Pract. 2016 Jun;6(3):220-229.

42.

Progressive Multiple Sclerosis.

Willis MA, Fox RJ.

Continuum (Minneap Minn). 2016 Jun;22(3):785-98. doi: 10.1212/CON.0000000000000323. Review.

PMID:
27261682
43.

Safety and Tolerability of Delayed-Release Dimethyl Fumarate Administered with Interferon Beta or Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis.

Calkwood J, Vollmer T, Fox RJ, Zhang R, Novas M, Sheikh SI, Viglietta V.

Int J MS Care. 2016 May-Jun;18(3):138-46. doi: 10.7224/1537-2073.2015-020.

44.

Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study.

Gold R, Arnold DL, Bar-Or A, Hutchinson M, Kappos L, Havrdova E, MacManus DG, Yousry TA, Pozzilli C, Selmaj K, Sweetser MT, Zhang R, Yang M, Potts J, Novas M, Miller DH, Kurukulasuriya NC, Fox RJ, Phillips TJ.

Mult Scler. 2017 Feb;23(2):253-265. doi: 10.1177/1352458516649037. Epub 2016 Jul 11.

45.

JC Polyomavirus Abundance and Distribution in Progressive Multifocal Leukoencephalopathy (PML) Brain Tissue Implicates Myelin Sheath in Intracerebral Dissemination of Infection.

Wharton KA Jr, Quigley C, Themeles M, Dunstan RW, Doyle K, Cahir-McFarland E, Wei J, Buko A, Reid CE, Sun C, Carmillo P, Sur G, Carulli JP, Mansfield KG, Westmoreland SV, Staugaitis SM, Fox RJ, Meier W, Goelz SE.

PLoS One. 2016 May 18;11(5):e0155897. doi: 10.1371/journal.pone.0155897. eCollection 2016.

46.

Relapses in multiple sclerosis: Relationship to disability.

Goodin DS, Reder AT, Bermel RA, Cutter GR, Fox RJ, John GR, Lublin FD, Lucchinetti CF, Miller AE, Pelletier D, Racke MK, Trapp BD, Vartanian T, Waubant E.

Mult Scler Relat Disord. 2016 Mar;6:10-20. doi: 10.1016/j.msard.2015.09.002. Epub 2015 Sep 8. Review.

PMID:
27063617
47.

Long-term registries: Answering tough questions with big data?

Fox RJ, Cutter G.

Neurol Clin Pract. 2016 Apr;6(2):97-99. doi: 10.1212/CPJ.0000000000000226. No abstract available.

48.

Erratum to: Reassessing the risk of natalizumab-associated PML.

Berger JR, Fox RJ.

J Neurovirol. 2016 Aug;22(4):536-537. No abstract available.

PMID:
27026534
49.

Relationship between symptom change, relapse activity and disability progression in multiple sclerosis.

Liu Y, Morgan C, Hornung L, Tyry T, Salter AR, Agashivala N, Belletti DA, Kim E, Fox RJ, Cofield SS, Cutter GR.

J Neurol Sci. 2016 Mar 15;362:121-6. doi: 10.1016/j.jns.2016.01.034. Epub 2016 Jan 19.

PMID:
26944131
50.

Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies.

Gold R, Giovannoni G, Phillips JT, Fox RJ, Zhang A, Marantz JL.

Neurol Ther. 2016 Jun;5(1):45-57. doi: 10.1007/s40120-016-0042-8. Epub 2016 Mar 1.

Supplemental Content

Support Center